ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO148

Serum Phosphorus and Pill Burden Decreases Among In-Center Hemodialysis (ICHD) Patients Switched to Sucroferric Oxyhydroxide for 12 Months

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical


  • Rastogi, Anjay, UCLA, Los Angeles, California, United States
  • Ficociello, Linda, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
  • Parameswaran, Vidhya, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
  • Mullon, Claudy, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
  • Kossmann, Robert J., Fresenius Medical Care North America, Waltham, Massachusetts, United States

According to DOPPS data, >75% of ICHD patients (pts) are prescribed phosphate binders (PB) for the control of serum phosphorus (sP); however, >35% of pts have hyperphosphatemia (sP>5.5 mg/dl). The current analysis is a 12-month follow-up on sP and PB pill burden changes in ICHD pts switched from another PB to sucroferric oxyhydroxide (SFO) as part of routine care.


This retrospective database analysis utilizes de-identified clinical data extracted from electronic health records from a large dialysis organization (LDO; DaVita Inc) and prescription records from the LDO’s pharmacy service. Adult ICHD pts who received 1 year of SFO monotherapy between 5/1/2014 and 9/30/2018 were included in the analysis. Baseline (BL) and follow-up (Q1-Q4) were divided into 3-month intervals. Mixed effects linear regression and Cochran's Q test were used to test for statistical significance.


Pts (n=364) had a mean BMI of 29.8 and dialysis vintage of 52.6 months. 53% of pts were male and most (74%) had a fistula for vascular access. Sevelamer was the most frequently prescribed monotherapy BL PB (64%), followed by calcium acetate (18%) and lanthanum carbonate (7%), and the remaining pts either switched between PB or had combination therapy. Comparisons between BL and SFO follow-up on mineral bone disease markers and PB pill burden are shown in Table. There were consistent improvements in pts achieving sP ≤5.5 mg/dL (increased from 18% at BL to 36.8-38.7% during SFO, p<0.001). Pts were prescribed an average of 9.3 pills/day at BL and 4.3 to 4.9 pills/day during Q1-Q4. Pts who achieved quarterly sP ≤ 5.5 mg/dl had a mean pill burden of 4.7 pills/day and mean sP of 4.72 mg/dL.


ICHD pts from an LDO prescribed to switch PB to SFO as part of routine care for 12 months, experienced significant reductions in sP along with a 47% reduction in PB pills/day and increase in the % of pts with sP ≤5.5 mg/dl.

PB pill burden (pills/day)9.34.3**4.7**4.8**4.9**<0.001
Serum phosphorus (mg/dL)6.776.13**6.07**6.08**6.13**<0.001
Patients with sP ≤ 5.5 mg/dL (%)18.436.8**38.7**38.5**38.7**<0.001
Patients with sP ≤ 4.5 mg/dL (%)3.611.5*11.8*14.3**12.4*<0.001
Serum calcium (mg/dL)9.08.979.09.08.980.47
Intact PTH (pg/mL)622650657*681**712**<0.001

* p<0.05; ** p<0.001


  • Commercial Support